VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Verastem, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.62−0.03 (-0.35%)
Close on Oct 19, 2026
- Market cap
- $863.00M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.60 (−6.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Verastem, Inc. reported revenue of $87.53M for the twelve months to Jun 30, 2026.
Revenue
$87.53M
TTM Q2 2026
Operating income
-$159.80M
TTM Q2 2026
EPS, diluted
-$2.55
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $863.00M
- P/E ratio
- –
- Price to sales
- 9.86
- Price to book
- 17.26
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $87.53M
- Net income
- -$202.70M
- EPS, diluted
- -$2.55
- Book value per share
- $0.50
- Diluted shares
- 100M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$87.53M
Gross profit
–
Operating income
-$159.80M
Net income
-$202.70M
EPS, diluted
-$2.55
Free cash flow
–
Reported periodTrailing twelve months